Colgate-Palmolive Company
CL
$88.10
+1.02%
Colgate-Palmolive Company is a global consumer staples leader founded in 1806, operating in the household and personal products industry. Its core business spans oral care (over 40% of sales), personal care (shampoos, shower gels, deodorants), home care, and the fast-growing Hill's Pet Nutrition segment (nearly one-fourth of sales). The company sells in over 200 countries, with approximately 70% of revenue generated internationally, including nearly half from emerging markets. As a defensive stalwart with a market cap of roughly $64 billion, Colgate is known for its resilient cash flows, brand equity, and consistent dividend. The current investor narrative centers on the company's ability to sustain mid-single-digit organic growth amid a rotation from growth to value stocks, as highlighted by recent news. However, the stock has underperformed the broader market over the past year, with a 7.6% gain versus SPY's 15% rise, raising questions about whether its premium valuation is justified. Management's focus on pricing, product innovation, and Hill's expansion are key catalysts, while foreign exchange headwinds and input cost pressures remain watch items.…
CL
Colgate-Palmolive Company
$88.10
Investment Opinion: Should I buy CL Today?
We assign a Hold rating on CL, balancing its defensive qualities and analyst optimism against deteriorating momentum and premium valuation. The consensus Buy rating (mean 2.05) and average target of $98.60 imply 17.0% upside, but the stock's 11.43% three-month decline and 14.77% underperformance versus SPY suggest the market is skeptical of this target. The core thesis is that CL offers stable cash flows and a 2.85% dividend yield, but lacks a near-term catalyst to reverse its downtrend.
Supporting evidence includes TTM free cash flow of $3.858 billion, which comfortably covers dividends and buybacks, and a gross margin expansion to 61.48% in Q2 2026. However, revenue growth decelerated to 4.91% YoY, operating margin fell to 18.95%, and the trailing PE of 29.93x is elevated relative to its historical range. The forward PE of 20.55x implies an earnings rebound that may be optimistic given the 85.5% payout ratio and 147.93% debt-to-equity. The PS ratio of 3.14x is below the 5-year average of 3.5x, but EV/EBITDA of 17.85x exceeds the historical 15x, indicating a mixed valuation picture.
The biggest risks are a continued margin compression, FX headwinds from 70% international exposure, and potential dividend strain. We would upgrade to Buy if the stock stabilizes above $90 and Q3 earnings show operating margin recovery above 20%, or if the forward PE compresses below 18x. We would downgrade to Sell if revenue growth falls below 3% or if the payout ratio exceeds 90%, signaling dividend risk. Relative to its history and peers, CL appears fairly valued to slightly overvalued, with the market pricing in a recovery that has yet to materialize.
Sign up to view all
CL 12-Month Price Forecast
CL presents a mixed picture: defensive qualities and a strong dividend are offset by slowing growth, margin pressure, and premium valuation. The stock's 11.43% three-month decline and 14.77% underperformance versus SPY suggest negative momentum that could persist until fundamental catalysts emerge. The forward PE of 20.55x prices in an earnings recovery that is not yet evident, leaving limited margin for error. We would upgrade to bullish if Q3 2026 shows operating margin recovery above 20% and revenue growth reaccelerates above 5%, or downgrade to bearish if the stock breaks below $74.55 on deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $98.35 and implied upside of +11.6% versus the current price.
Average Target
$98.35
0 analysts
Implied Upside
+11.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$87 - $110
Analyst target range
Colgate is covered by 20 analysts, with a consensus recommendation of "Buy" (mean rating 2.05, where 1 is Strong Buy and 5 is Strong Sell). The average price target is $98.60, implying an upside of 17.0% from the current price of $84.26. The consensus leans bullish, with a majority of analysts maintaining positive ratings, as evidenced by recent actions from Piper Sandler (Overweight), RBC Capital (Outperform), and JP Morgan (Overweight). However, the stock's recent underperformance and the wide gap between the current price and the average target suggest that analysts may be slow to adjust their estimates downward.
The target price range spans from a low of $87.00 to a high of $110.00. The high target of $110 assumes a significant re-rating, likely driven by accelerating growth in Hill's Pet Nutrition, margin expansion, and successful new product launches. The low target of $87, which is still 3.3% above the current price, implies modest growth and stable margins, but does not price in a severe downturn. The spread between the low and high targets is $23, or about 26% of the average target, indicating moderate uncertainty. Institutional ratings show a mix of Overweight, Outperform, and Hold ratings, with no recent downgrades, suggesting that analysts remain constructive despite the stock's weak price action. The estimated EPS average of $4.79 for the current year provides a forward PE of 17.6x, which is more reasonable than the trailing multiple.
Bulls vs Bears: CL Investment Factors
The bear case currently holds stronger evidence due to CL's severe relative underperformance (-14.77% vs. SPY over 3 months), decelerating revenue growth (4.91% YoY in Q2 2026 vs. 8.4% in Q1), and operating margin compression (18.95% vs. 21.14%). While the analyst consensus remains bullish with a $98.60 target, this optimism appears stale given the stock's 11.43% three-month decline and failure to hold above $90. The most critical tension is whether the forward PE of 20.55x—implying significant earnings recovery—can be justified by Hill's growth and margin stabilization, or if further multiple compression is warranted. If Q3 earnings fail to show margin improvement, the stock could test the 52-week low of $74.55, representing 11.5% downside.
Bullish
- Analyst Consensus Buy with 17% Upside: 20 analysts rate CL a Buy (mean 2.05) with an average target of $98.60, implying 17.0% upside from $84.26. Even the lowest target of $87.00 sits 3.3% above the current price, suggesting a favorable risk/reward skew.
- Defensive Low-Beta Stalwart: CL's beta of 0.323 means it is roughly 68% less volatile than the S&P 500, offering portfolio stability in turbulent markets. Its 2.85% dividend yield and 85.5% payout ratio further reinforce its income-oriented appeal.
- Strong Free Cash Flow Generation: TTM free cash flow of $3.858 billion comfortably covers $462 million in quarterly dividends and $291 million in buybacks. This cash generation supports continued shareholder returns even amid earnings volatility.
- Hill's Pet Nutrition Growth Engine: Hill's contributes nearly one-fourth of sales and continues to outpace the core business, providing a higher-growth, higher-margin catalyst. Its expansion into vet and specialty channels offers a structural tailwind.
Bearish
- Severe Relative Underperformance: CL has lagged the S&P 500 by 14.77% over three months and 18.38% over six months, with a 1-month decline of 6.48% versus SPY's 0.59% gain. This persistent weakness signals waning investor confidence and potential further downside.
- Premium Valuation on Stagnant Growth: The trailing PE of 29.93x is near the upper end of its historical range, while revenue growth decelerated to 4.91% in Q2 2026 from 8.4% in Q1. The market is paying a premium for growth that is slowing.
- Operating Margin Compression: Operating margin fell to 18.95% in Q2 2026 from 21.14% a year ago, pressured by higher SG&A and a $150 million other expense. This erosion, if sustained, could undermine the earnings rebound implied by the forward PE.
- Elevated Leverage and Weak Liquidity: Debt-to-equity stands at 147.93% and the current ratio is 0.995, meaning current liabilities exceed current assets. This capital structure leaves little cushion if cash flows deteriorate.
CL Technical Analysis
Colgate-Palmolive is currently in a medium-term downtrend, with the stock trading at $84.26 as of October 2, 2026. Over the past year, the shares have gained 7.6%, but they sit only 32.6% above the 52-week low of $74.55 and 15.2% below the 52-week high of $99.33. This places the current price at approximately 41.5% of the 52-week range, indicating a bearish positioning that suggests weakening momentum rather than a value opportunity, given the recent price action. The stock has been making lower highs since July 2026, when it peaked near $95, and the failure to hold above $90 has reinforced the downtrend.
Short-term momentum is clearly negative: the stock is down 6.48% over the past month and 11.43% over the past three months, significantly underperforming the S&P 500, which gained 0.59% and 3.34% over the same periods. This divergence from the longer-term trend (still positive on a 1-year basis) signals a potential trend reversal or at least a deep correction. The relative strength versus SPY is -7.07% for 1 month and -14.77% for 3 months, confirming that Colgate is a notable laggard. Volume of 6.6 million shares on the latest day is moderate, but the lack of positive momentum suggests sellers remain in control.
Key technical support lies at the 52-week low of $74.55, while resistance is at the 52-week high of $99.33. A breakdown below $74.55 would likely accelerate selling pressure and signal a deeper bear market, whereas a breakout above $99.33 would require a significant shift in sentiment and could trigger a new uptrend. The stock's beta of 0.323 indicates very low volatility relative to the market—about 68% less volatile than SPY—which may appeal to risk-averse investors but also means it often lags in strong bull markets. The maximum drawdown of -17.48% over the past year reflects the stock's defensive nature but also its recent struggles.
Beta
0.32
0.32x market volatility
Max Drawdown
-17.5%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
+12.9%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | -0.4% | +1.0% |
| 3m | -4.5% | +2.5% |
| 6m | +4.5% | +13.9% |
| 1y | +12.9% | +15.0% |
| ytd | +13.4% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Colgate's revenue trajectory remains stable but unexciting. In Q2 2026, the company reported revenue of $5.361 billion, up 4.91% year-over-year from $5.110 billion in Q2 2025. This growth is driven by both the Oral, Personal and Home Care segment ($4.166 billion) and Hill's Pet Nutrition ($1.195 billion), with Hill's continuing to outpace the core business. However, the growth rate has decelerated from prior quarters: Q1 2026 revenue was $5.324 billion (up 8.4% YoY), and Q4 2025 was $5.230 billion (up 5.8% YoY). The sequential slowdown suggests that pricing power may be waning and volume growth is modest, which could pressure the investment case if the trend continues.
Profitability remains robust, with a net income of $693 million in Q2 2026 and a net margin of 12.93%. The gross margin stood at 61.48%, slightly above the 60.06% in Q2 2025, indicating some margin expansion despite cost inflation. Operating margin was 18.95%, down from 21.14% a year ago, largely due to higher selling, general and administrative expenses and a $150 million other expense. The company's return on equity is exceptionally high at 39.48%, but this is inflated by a very low equity base due to significant share buybacks and debt. The net margin of 10.46% (TTM) is typical for the household products industry, but the operating margin compression bears watching.
Colgate's balance sheet carries substantial leverage, with a debt-to-equity ratio of 147.93%, reflecting a capital structure heavily weighted toward debt. The current ratio is 0.995, slightly below 1, indicating that current liabilities exceed current assets, which could pose a liquidity risk if not managed. However, free cash flow remains strong: TTM FCF is $3.858 billion, and the company generated $867 million in FCF in Q2 2026 alone. This cash flow easily covers dividends ($462 million in Q2) and share repurchases ($291 million), but the high payout ratio of 85.5% leaves little room for error. The company's ROA of 15.84% is healthy, but the debt burden and low current ratio warrant monitoring.
Quarterly Revenue
$5.4B
2026-06
Revenue YoY Growth
+4.9%
YoY Comparison
Gross Margin
61.5%
Latest Quarter
Free Cash Flow
$3.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Since Colgate is profitable with positive net income, the PE ratio is the primary valuation metric. The trailing PE is 29.93x, while the forward PE is 20.55x, implying that the market expects significant earnings growth in the coming year. This large gap between trailing and forward multiples suggests that analysts anticipate a rebound in profitability, possibly from margin recovery or lower restructuring costs. However, the trailing PE is elevated compared to the broader market and the company's own history, which may indicate that the stock is priced for perfection.
Compared to the household and personal products industry, Colgate's valuation appears rich. The industry average PE is not provided, but the stock's PS ratio of 3.14x and EV/EBITDA of 17.85x are above typical sector levels. For context, the S&P 500 consumer staples sector often trades at a forward PE of around 20x, so Colgate's forward PE of 20.55x is roughly in line, but its trailing PE of 29.93x represents a premium. The PEG ratio is negative (-1.19), which is not meaningful due to the earnings decline in Q4 2025. The high PB ratio of 1183x is distorted by the low book value of equity. Overall, the valuation seems stretched unless growth accelerates.
Historically, Colgate's PE ratio has ranged from the low 20s to the low 30s over the past few years. The current trailing PE of 29.93x is near the upper end of that range, while the forward PE of 20.55x is more moderate. The PS ratio of 3.14x is lower than the 5-year average of around 3.5x, but the EV/EBITDA of 17.85x is above the historical average of 15x. This mixed picture suggests that while the stock is not cheap, it is not excessively overvalued relative to its own history. However, the high payout ratio and low growth may limit multiple expansion.
PE
29.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 21x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.5x
Enterprise Value Multiple
Investment Risk Disclosure
Colgate's financial risks are anchored in its leveraged balance sheet and tight liquidity. The debt-to-equity ratio of 147.93% and current ratio of 0.995 indicate that current liabilities exceed current assets, leaving minimal buffer if cash flows weaken. The 85.5% payout ratio consumes most net income, limiting financial flexibility; any earnings shortfall could jeopardize the dividend or buyback program. Additionally, operating margin compression to 18.95% in Q2 2026 from 21.14% a year ago, driven by higher SG&A and a $150 million other expense, highlights vulnerability to cost inflation and restructuring charges.
Market and competitive risks stem from CL's premium valuation amid slowing growth. The trailing PE of 29.93x is near the high end of its historical range, while revenue growth decelerated to 4.91% in Q2 2026 from 8.4% in Q1. With a beta of 0.323, the stock is defensive but may lag in strong bull markets, as evidenced by its 18.38% underperformance versus SPY over six months. The recent rotation from growth to value stocks, as noted in news, could further pressure consumer staples if investors favor higher-growth sectors. Competitive threats in oral care and pet nutrition, plus foreign exchange headwinds from 70% international sales, add to the risk profile.
The worst-case scenario involves a sustained earnings miss triggering analyst downgrades and multiple compression. If Q3 2026 results show continued margin erosion and revenue growth below 4%, the stock could break below its 52-week low of $74.55, representing an 11.5% decline from the current $84.26. A more severe downturn, such as a global recession hitting emerging markets (nearly half of sales), could push the stock toward the analyst low target of $87.00—though that is above current levels—or lower. Historically, the max drawdown over the past year was -17.48%, implying a potential loss of approximately 17% from recent highs, but a perfect storm of margin compression, FX headwinds, and dividend concerns could result in a 20-25% decline to the low $60s.
FAQ
The most severe risk is margin compression, with operating margin falling to 18.95% in Q2 2026 from 21.14% a year ago. Financial leverage is another concern, with a debt-to-equity of 147.93% and a current ratio below 1. The high payout ratio of 85.5% limits flexibility and could lead to a dividend cut if earnings decline. Additionally, 70% of sales are international, exposing the company to foreign exchange headwinds and emerging market volatility. Competitive pressures in oral care and pet nutrition also pose threats.
Our 12-month forecast has a base case (55% probability) of $87-$99, a bull case (25%) of $99-$110, and a bear case (20%) of $74-$87. The base case assumes revenue growth stabilizes around 4-5% and operating margin holds near 19-20%. The bull case requires a margin recovery above 20% and accelerating Hill's growth, while the bear case involves a breakdown below the 52-week low on worsening fundamentals. The most likely scenario is the base case, with the stock gravitating toward the analyst average target of $98.60.
CL appears fairly valued to slightly overvalued. The trailing PE of 29.93x is near the upper end of its historical range, while the forward PE of 20.55x is more moderate but still above the broader market. The PS ratio of 3.14x is below the 5-year average of 3.5x, but EV/EBITDA of 17.85x exceeds the historical 15x. The market is pricing in an earnings recovery that has yet to materialize, given the 4.91% revenue growth and 18.95% operating margin. Compared to peers, CL's valuation is rich, especially considering its low growth.
From a risk/reward perspective, CL offers a modest upside of 17.0% to the analyst average target of $98.60, but the downside risk to the 52-week low of $74.55 is 11.5%. The stock's defensive nature (beta 0.323) and 2.85% dividend yield make it suitable for conservative investors, but its recent underperformance (-14.77% vs. SPY over 3 months) and premium trailing PE of 29.93x suggest caution. It may be a good buy for income-oriented investors willing to wait for a turnaround, but growth investors should look elsewhere. A better entry point might be near the 52-week low of $74.55.
CL is best suited for long-term, income-focused investors due to its defensive characteristics, low beta (0.323), and 2.85% dividend yield. Short-term trading is less attractive given the stock's negative momentum and 11.43% three-month decline. The company's stable cash flows and brand equity support a buy-and-hold strategy, but investors should be prepared for continued underperformance if growth remains sluggish. A minimum holding period of 2-3 years is recommended to ride out cyclical downturns and benefit from potential margin recovery.